One Anti-ST2 Biologic, Three Gateways: What an Alarmin-Targeted Monoclonal Antibody Candidate's Regulatory Path Reveals About Parallel Health Canada, FDA, and EMA Clinical Trial Authorization

Anti-ST2 monoclonal antibodies neutralize the interleukin-33 receptor, blocking a key upstream alarmin signalling pathway implicated in airway inflammation, and represent a biologic class under continued investigation for chronic obstructive pulmonary disease (COPD) exacerbation reduction, an area with limited targeted biologic options relative to severe asthma. This article uses a hypothetical multinational Phase 2 clinical trial of an anti-ST2 monoclonal antibody candidate, sponsored by a fictional company, to compare the Clinical Trial Application (CTA) process required by Health Canada, the Investigational New Drug (IND) process required by the U.S. Food and Drug Administration, and the Clinical Trial Application process required by the European Medicines Agency under Regulation (EU) No 536/2014. As a large-molecule biologic governed by ICH S6(R1) principles rather than the small-molecule nonclinical framework, this candidate illustrates how species-relevant pharmacology and immunogenicity considerations carry through the administrative layer of all three regions even though the core harmonized scientific content, Modules 2 through 5 of the Common Technical Document and their EU IMPD equivalent, remains substantially shared. The article addresses the operational challenges specific to a respiratory biologic program conducted across these three jurisdictions, the ways artificial intelligence tools are used, and can responsibly be used, in preparing and administering this kind of regulatory package, and closes with recommendations for regulatory operations teams managing monoclonal antibody candidates in chronic respiratory disease.Keywords: anti-ST2 monoclonal antibody; chronic obstructive pulmonary disease; Clinical Trial Application; Investigational New Drug; Regulation (EU) No 536/2014; ICH S6(R1); regulatory artificial intelligence